Explore

9/11 First Responders Advocate for Dementia Coverage Under World Trade Center Health Program

9/11 First Responders Advocate for Dementia Coverage Under World Trade Center Health Program

Twenty-five years after the 9/11 attacks, first responders are increasingly being diagnosed with dementia, prompting a push for the condition to be covered by the World Trade Center Health Program. Researchers believe there is a connection between exposure to toxins at Ground Zero and the emerging health crisis of dementia among these individuals. Currently, dementia is not among the conditions recognized for coverage under the program. NBC News’ Tom Llamas reported on this issue as part of the series “The Cost of Denial,” highlighting the challenges faced by those who served at Ground Zero and are now experiencing these severe cognitive impairments. The advocacy aims to expand the scope of the health program to include dementia, acknowledging the long-term health consequences of their service.

Ketamine Offers Rapid Relief for PTSD Symptoms, Contrasting with EMDR's Gradual Approach

Ketamine Offers Rapid Relief for PTSD Symptoms, Contrasting with EMDR's Gradual Approach

Ketamine is emerging as a rapid-acting treatment for Post-Traumatic Stress Disorder (PTSD), with some patients experiencing symptom relief within hours to days. This contrasts with Eye Movement Desensitization and Reprocessing (EMDR), a guideline-recommended psychotherapy that typically takes weeks to months to show significant improvement. While EMDR is a structured therapy that helps reprocess traumatic memories, ketamine works on brain chemistry, specifically the glutamate system, to increase neuroplasticity and make entrenched patterns of fear more flexible. Ketamine is currently used off-label for PTSD, meaning it is not FDA-approved for this specific condition, unlike EMDR which is a first-line treatment. Both treatments have demonstrated effectiveness in bringing a majority of patients to meaningful improvement, with similar rates of response and remission in studies, though direct head-to-head trials are lacking. Ketamine can be administered in various settings, including in-clinic IV infusions, in...

Brain Gray Matter Decline Pauses During Menopause Transition, Study Reveals

Brain Gray Matter Decline Pauses During Menopause Transition, Study Reveals

A new study published in Nature Communications indicates that the gradual decline in brain gray matter, a normal part of aging, temporarily pauses during the transition to menopause. Researchers analyzed MRI scans from over 1,000 girls and women, comparing brain changes across puberty, pregnancy, and menopause. While gray matter volume typically shrinks during puberty and pregnancy, reflecting neural fine-tuning, the study found a unique stability during late perimenopause. This pause in decline then resumes in postmenopausal women. Study co-author Sophie van't Hof, a doctoral student at Amsterdam University Medical Center, noted that factors like hormone replacement therapy or the number of children did not significantly impact these results. The research provides the first direct longitudinal comparison of brain structural changes across these major female hormonal transitions.

Psychiatrist Alan M. Langlieb Advocates for Comprehensive Patient Understanding Beyond Prescriptions

Psychiatrist Alan M. Langlieb Advocates for Comprehensive Patient Understanding Beyond Prescriptions

Dr. Alan M. Langlieb, a Johns Hopkins-trained psychiatrist, argues against dismissing patients who self-medicate and advocates for a more holistic approach to mental health care. He emphasizes that substances patients use, whether prescribed or not, offer crucial clues to their underlying symptoms and life circumstances. Dr. Langlieb highlights that the healthcare system often focuses too narrowly on prescribed medications, neglecting the 'other half' of a patient's chemical life, which includes alcohol, cannabis, nicotine, caffeine, kratom, stimulants, sedatives, and supplements. He suggests that understanding the 'half-life' of substances, both prescribed and self-administered, is essential, as their effects can lead to cycles of relief and rebound, potentially exacerbating distress. His approach involves a judgment-free inventory of all substances a patient uses, mapping their daily use, benefits, and costs to build a safer and more coherent treatment plan.

Medication Management Essential for Effective Psychiatric Treatment and Patient Well-being

Medication Management Essential for Effective Psychiatric Treatment and Patient Well-being

Medication management is highlighted as an ongoing and crucial process for ensuring the safety and effectiveness of psychiatric treatment. It involves regular follow-up appointments, symptom monitoring, side-effect review, medication adjustments, and coordination with other aspects of a patient's care. Providers assess how medication impacts mood, sleep, energy, focus, and daily life, ensuring it aligns with the patient's diagnosis and overall health. Initial appointments are comprehensive, covering current symptoms, past diagnoses, previous medications, side effects, and treatment goals. Follow-up visits are essential because many psychiatric medications, such as antidepressants, take time to show full effects, and ongoing monitoring helps determine if adjustments are needed or if the medication remains beneficial. Patients are encouraged to actively communicate changes in symptoms or side effects to their providers.

USC Researchers Develop Blood-Based Algorithm to Enhance Alzheimer's Trial Screening

USC Researchers Develop Blood-Based Algorithm to Enhance Alzheimer's Trial Screening

Researchers at the Keck School of Medicine of the University of Southern California (USC) have developed a blood-plasma screening algorithm designed to improve the efficiency of recruiting participants for Alzheimer's prevention trials. This new tool aims to identify individuals more likely to meet the amyloid thresholds required for trial enrollment, thereby reducing the need for costly and time-consuming positron emission tomography (PET) scans. The algorithm integrates two plasma biomarkers: the amyloid-beta ratio, which indicates early brain amyloid, and phosphorylated tau 217 (p-tau217), a direct marker of amyloid burden. Additionally, age and apolipoprotein E4 (APOE4) carrier status are factored in to refine individual risk estimates. The development of this algorithm utilized data from 1,080 participants in the AHEAD 3-45 phase 3 trial and was validated using an independent cohort from the Wisconsin Registry for Alzheimer’s Prevention. The algorithm was iteratively refined during the AHEAD trial's r...

Neuroscientist Jack Feldman Explains How Breathing Influences Brain Activity and Emotional States

Neuroscientist Jack Feldman Explains How Breathing Influences Brain Activity and Emotional States

Professor Jack Feldman, a distinguished neurobiology professor at the University of California at Los Angeles, has extensively researched the profound connection between breathing and brain function, particularly how it influences emotional and cognitive states. Feldman's work, which includes the discovery of the preBötzinger complex—the brain circuit controlling sighing—demonstrates that breathing is not merely an automatic physiological process but actively rewrites brainwaves, sharpens memory, and dictates how individuals process the world. He explains that a tiny cluster of neurons in the brainstem orchestrates breathing, and this process is a two-way street: while the brain controls breathing, breathing also influences the brain. His research indicates that practices like slow breathing can significantly reduce fear responses and promote calmness, as observed in animal studies where mice trained to breathe slowly exhibited lower fear levels.

SSRIs and SNRIs Remain Primary Pharmacological Treatments for PTSD

SSRIs and SNRIs Remain Primary Pharmacological Treatments for PTSD

The most commonly prescribed medications for Post-Traumatic Stress Disorder (PTSD) are selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). These antidepressants are primarily used to reduce the intensity of PTSD symptoms such as anxiety, low mood, and sleep disturbances, thereby making it easier for individuals to engage in therapy. While medication does not erase traumatic memories, it can significantly alleviate the distress associated with them. Doctors typically adjust dosages or try different medications if the initial prescription does not yield noticeable effects within several weeks. Other medications, such as certain blood pressure medications for trauma-related nightmares or short-term sleep aids, may also be used for specific problems. However, sedative medications like benzodiazepines are generally not recommended for long-term PTSD treatment due to their potential to interfere with recovery and risk of dependence.

Anti-Inflammatory Diets May Alleviate Fatigue and Improve Physical Health in Multiple Sclerosis Patients

Anti-Inflammatory Diets May Alleviate Fatigue and Improve Physical Health in Multiple Sclerosis Patients

A new analysis of clinical trial data suggests that anti-inflammatory diets could help reduce fatigue and enhance overall physical health in individuals with multiple sclerosis (MS). The findings indicate that while these diets may offer benefits for physical well-being, they do not significantly alter body composition, disability status, or mental health in MS patients. Researchers emphasize that more studies are needed to fully understand the influence of various diets on MS. MS is an inflammatory disease affecting the brain and spinal cord, and many studies have explored dietary impacts on its symptoms. Currently, there is insufficient data to definitively state that one diet is superior for MS, leading to general advice for patients to follow a well-balanced diet rich in fruits and vegetables and low in processed foods. Given that MS is driven by inflammation, some research has investigated whether anti-inflammatory diets, often based on complementary and alternative medicine approaches, could provide ...

Brain's Fuel System Recovers Rapidly After Cessation of Heavy Drinking, Study Finds

Brain's Fuel System Recovers Rapidly After Cessation of Heavy Drinking, Study Finds

New research indicates that the brain's metabolic adaptations to heavy alcohol consumption are highly reversible once an individual stops drinking. The study, published in Neuropsychopharmacology, found that after one week of abstinence, individuals with alcohol use disorder showed a significant, 64 percent lower rate of brain acetate oxidation compared to heavy drinkers. Acetate is a secondary fuel source derived from alcohol that the brain increasingly relies on during chronic heavy drinking. Surprisingly, this metabolic slowdown was temporary, with brain acetate consumption increasing by 43 percent after one month of abstinence, becoming nearly indistinguishable from that of light drinkers. This suggests a rapid readjustment of the brain's energy systems to function without alcohol. The study involved four groups: light drinkers, heavy drinkers, individuals in long-term recovery, and those undergoing medically supervised inpatient detoxification.

Compass Pathways Reports Positive 52-Week Data for COMP360 Psilocybin in Treatment-Resistant Depression

Compass Pathways Reports Positive 52-Week Data for COMP360 Psilocybin in Treatment-Resistant Depression

Compass Pathways, a biotechnology company, has released positive 52-week topline results from Part C of its Phase 3 COMP005 trial for COMP360 psilocybin, an investigational treatment for treatment-resistant depression (TRD). The data indicates that an additional dose of COMP360 25 mg provided further benefit, leading to an average 13-point reduction from baseline in MADRS scores at Week 52, with durability extending out to one year for participants who received an additional dose. For participants who initially received a placebo and then their first dose of COMP360 25 mg in Part C, the findings reinforced that a single dose can produce rapid onset, meaningful effect, and durability. Across all participants who received a 25 mg dose in Part C, response rates of 40%-45% and remission rates of approximately 30% were observed within six weeks. The safety profile of COMP360 in Part C remained consistent with previous parts of the trial, showing a generally well-tolerated and safe profile without new safety fin...

Gene Therapy Extends Lifespan and Reduces Symptoms in Feline Sandhoff Disease Model

Gene Therapy Extends Lifespan and Reduces Symptoms in Feline Sandhoff Disease Model

A new study has demonstrated that intravenous gene therapy can extend the lifespan and reduce symptoms in a cat model of Sandhoff disease. Sandhoff disease, along with Tay-Sachs disease, is a fatal neurodegenerative lysosomal storage disorder characterized by the toxic accumulation of fat in nerve cells of the brain and spinal cord due to the absence of β-hexosaminidase (Hex) enzymes. Currently, there are no available therapies for these conditions, which typically lead to the death of affected children around four years of age. The gene therapy tested in this study utilized an adeno-associated virus (AAV) vector expressing the two Hex enzymes. Previous clinical trials for Sandhoff disease involved injecting AAV gene therapy directly into the brain or cerebrospinal fluid. However, this new research, published in Science Translational Medicine, marks the first time intravenous AAV gene therapy has been evaluated for this condition. The study investigated the delivery of a bicistronic AAV vector to presympto...